The association between inpatient hyperglycemia and adverse patient outcomes is well documented.\textsuperscript{1-7} Thus, focus on inpatient glycemic control has increased in the past decade. However, optimal glycemic targets remain controversial, and significant barriers to optimal glycemic control persist.

**Inpatient Glycemic Targets**

After publication of the initial van den Berghe trial in surgical intensive care patients,\textsuperscript{1} several professional organizations published guidelines supporting near-normal glycemic targets.\textsuperscript{8,9} Subsequent trials documented an increased risk for hypoglycemia with tight glycemic control, suggesting that more modest glycemic targets may be optimal.\textsuperscript{10-13} The Normoglycemia in Intensive Care Evaluation–Survival Using Glucose Algorithm Regulation (NICE-SUGAR) study,\textsuperscript{14} a large, randomized trial involving >6,100 medical and surgical patients, documented higher 90-day mortality rates in patients managed with tight glycemic control than in those receiving conventional glucose management. Although hypoglycemia was more common among patients in the intensive treatment group, the association of hypoglycemia with an increased hazard ratio for death was similar in the two groups, suggesting that hypoglycemia contributed to the excess mortality in the intensively treated group.\textsuperscript{15}

The increased risk for hypoglycemia and mortality with tight glycemic control does not justify ignoring glycemic control, but it does justify setting more moderate targets. The American Diabetes Association (ADA), the American Association of Clinical Endocrinologists (AACE), the Surviving Sepsis Campaign, and the Institute for Healthcare Improvement all updated their guidelines for glycemic control in 2009 in response to data from NICE-SUGAR.\textsuperscript{16-18} All four sets of guidelines recommend initiating insulin therapy in patients with persistent hyperglycemia (blood glucose > 180 mg/dl). After insulin is initiated, the target blood glucose range should be 140–180 mg/dl for the majority of patients. However, a more stringent goal of 110–140 mg/dl may be appropriate for certain patients, provided it can be achieved without causing significant hypoglycemia. The Society of Critical Care Medicine recommends a slightly different target of 100–150 mg/dl, while still focusing on minimizing the risk for hypoglycemia.\textsuperscript{19}

**Rationale for Continuous Insulin Infusion**

Insulin is the preferred treatment modality in the hospital setting because it is the most potent agent to lower blood glucose, is rapidly effective, is easily titrated, and has no absolute contraindications.\textsuperscript{18,20} However, insulin is a high-alert medication that is consistently implicated in reports of preventable patient harm (from hypoglycemia) and thus requires accurate monitoring and standardized protocols to minimize risks while maximizing benefits.\textsuperscript{21-24}

Intravenous (IV) infusion is the preferred route of insulin delivery in critical care, labor and delivery, and perioperative inpatient settings because the rapid onset and short duration of action associated with IV
infusion allow for matching insulin requirements to rapidly changing glucose levels. Table 1 provides additional potential indications for IV insulin infusion. Sliding-scale or correction algorithms with regular or rapid-acting insulin administered as needed for hyperglycemia without scheduled basal insulin or prandial insulin (for patients who are eating) are outdated treatment modalities that should be abandoned. Data are lacking to support the benefit of sliding-scale insulin or correction insulin algorithms without basal insulin, and these practices are associated with wide fluctuations in blood glucose, which have been linked to higher hospital mortality rates.25

Insulin infusion may be an alternative to a basal-bolus insulin regimen outside of the critical care setting for perioperative and other patients who are not eating (NPO status) and patients whose glycemia is poorly controlled with subcutaneous insulin. Insulin infusion can be safely administered outside of the critical care setting provided staff education, nurse-to-patient ratios, and blood glucose monitoring are adequate.20,26 In addition, setting more moderate glycemic targets for patients outside of the critical care setting may minimize nursing time for blood glucose monitoring and titration of the insulin infusion. For patients starting parenteral or enteral nutrition, the use of IV insulin infusion with appropriate monitoring may allow for more rapid titration and determination of patients’ insulin requirements than one could expect from either a subcutaneous insulin regimen or from the practice of including insulin in the parenteral nutrition solution. The use of IV insulin infusion in patients who are eating or are receiving intermittent enteral/parenteral nutrition requires proactive increases in infusion rate with the start of nutritional intake and decreases when nutritional intake is stopped, and thus, in most situations, conversion to subcutaneous insulin is appropriate because it is less labor intensive.

### Table 1. Potential Indications for IV Insulin Therapy

| Indication                                      |
|------------------------------------------------|
| Diabetic ketoacidosis                          |
| Hyperglycemic, hyperosmolar state              |
| Critical care illness (medical/surgical)        |
| Post-cardiac surgery                           |
| Myocardial infarction or cardiogenic shock      |
| Prolonged NPO status in patients who are insulin deficient |
| Labor and delivery                             |
| Uncontrolled hyperglycemia during high-dose glucocorticoid therapy |
| Perioperative period                            |
| Post-organ transplantation                      |
| Stroke                                         |
| Total parenteral nutrition therapy             |
| Dose-finding strategy before converting a patient to subcutaneous insulin |

Selecting an Insulin Infusion Protocol

Numerous insulin infusion protocols have been published. However, head-to-head comparisons are rare, and efficacy and safety are difficult to determine because of differing patient populations, glycemic targets, metrics for evaluation, and definitions of hypoglycemia used in the various protocols.26,33–37 Selecting a validated protocol allows for more rapid implementation but does not eliminate the need for ongoing safety and effectiveness monitoring and continuous quality improvement.

Some paper protocols are table-based, whereas others require mathematical calculations. The level of clinical judgment and physician oversight also varies among the available protocols. Computerized protocols allow for more complex mathematical calculations and can provide alerts or alarms to remind staff members to check patients’ blood glucose level and adjust infusion rates.

Several studies comparing computerized and paper-based protocols have found improved protocol adherence, improved glycemic control, and less hypoglycemia with computerized protocols.38–49 It is worth noting that evaluations of computerized glucose control programs have used glycemic targets that are tighter than currently recommended, and although the percentages of blood glucose readings within the target range were higher than with paper protocols, they still were not optimal in most studies. It is not clear how computerized glucose control programs compare to paper-based protocols when currently recommended targets are used.

Several computerized decision-support systems for insulin infusion management are commercially available; however, licensing fees and
Table 2. Components of a Safe and Effective Insulin Infusion Protocol

- Includes appropriate glycemic targets
- Identifies threshold for implementation
- Is nurse-managed and easy to implement
- Provides clear, specific directions for blood glucose monitoring and titration
- Includes titration based on both current blood glucose level and rate of change*
- Is safe: carries a low risk for hypoglycemia and includes an embedded protocol for treatment of hypoglycemia should it occur
- Is effective: gets patients to target quickly and maintains blood glucose within the target range with minimal titration
- Includes a plan for transition to subcutaneous insulin

*Rate of change is calculated based on the slope of the blood glucose trend line and is frequently incorporated into column-based protocols by movement to a more aggressive algorithm if blood glucose is not declining by ~ 40–75 mg/dl or to a less aggressive algorithm if blood glucose is declining too rapidly.
and the use of some medications (e.g., mannitol, icodextrin/maltose, and acetaminophen). The degree of interference and thus inaccuracy of the blood glucose measurement varies depending on the concentration of the interfering substance and the POC methodology (e.g., glucose oxidase vs. glucose dehydrogenase). Thus, it is important to carefully assess the specific device limitations and patient populations to optimize quality control policies and procedures. There is concern that the safety and effectiveness of POC blood glucose monitoring systems are not sufficiently evaluated in hospitalized acutely ill patient populations before marketing. The U.S. Food and Drug Administration has issued draft recommendations requiring additional testing of POC blood glucose monitoring devices for use in the hospital setting before approval.

Arterial or venous whole blood sampling is recommended instead of finger-stick capillary testing for patients in shock, receiving vasopressor therapy, or with severe peripheral edema. In these situations, samples from an arterial or venous site should be used. Bedside POC blood gas analyzers are frequently used in the operative and critical care settings and can be used to monitor blood glucose, as well as electrolytes and blood gases. However, they require a larger volume of blood, are substantially more expensive, and utilize the same methodology (glucose oxidase) as many of the available POC blood glucose meters. Any time a POC blood glucose value does not match the clinical situation, it should be verified with a repeat test or laboratory blood glucose determination.

Continuous glucose sensors are available for ambulatory patients and have demonstrated benefits in select patients over intermittent POC testing. However, data are mixed regarding the performance of these U.S. Food and Drug Administration–approved ambulatory devices in the critical care setting. Preclinical testing of an intravascular continuous glucose monitoring sensor has been promising. Perhaps in the future, the use of continuous glucose sensors in combination with a computerized decision-support system for insulin therapy will improve the safety of insulin infusion therapy for critically ill patients, allowing for the achievement of tighter glycemic goals without hypoglycemia.

Staff Education
The safety of any insulin infusion protocol is tied to the ability of staff members to understand and follow the protocol; thus, ongoing education and competence assessment are crucial. The best educational approach is a varied one that allows for differing learning styles and working schedules and that can be repeated at frequent intervals. Each institution will have unique educational needs; thus, the education plan will differ from site to site. However, education is a key component of successful insulin infusion protocols in all settings.

Metrics for Evaluating Insulin Infusion Protocols
Ongoing evaluation of efficacy and safety is also crucially important to the successful implementation of an insulin infusion protocol. Such evaluation facilitates continuous improvement and staff education and builds momentum to support expansion of the protocol into additional patient populations or additional settings within the institution. Evaluation metrics can be as simple as tracking 1) mean or median blood glucose with standard deviations or interquartile ranges by unit or patient population and 2) incidence of hypoglycemia. It is also important to evaluate glucose variability because increased variability is also associated with poor patient outcomes. Depending on the institution’s specific goals and barriers, metrics can include more advanced evaluation, including financial analysis. Several institutions have published their metrics and financial impact assessments. Similar to staff education, evaluation metrics will differ from one institution to another but remain a crucial tool for safe and effective insulin infusion programs in all institutions.

Transition from IV to Subcutaneous Insulin
To avoid loss of glycemic control and optimize patient outcomes, it is important that patients are appropriately transitioned from IV to subcutaneous insulin. This is especially important for patients with type 1 diabetes, because they can develop DKA if scheduled basal insulin and prandial insulin (for patients who are eating) are not initiated before stopping the insulin infusion. A transition protocol provides guidance regarding which patients are likely to require transition to subcutaneous insulin and when and how to make the transition. Patients with type 1 diabetes and most patients with type 2 diabetes who were treated with insulin before hospitalization will require such a transition. In addition, patients receiving > 2 units/hour of insulin on the infusion protocol will likely require subcutaneous insulin unless there is a significant change in their clinical situation, such as discontinuation of parenteral/enteral nutrition, tapering of steroids, or gastric bypass surgery.

The appropriate timing for the transition from IV to subcutaneous insulin depends on institutional policies regarding where and when insulin infusion can be used. Ideally, the transition occurs when patients begin an oral diet and their blood glucose levels are stable within the target range. IV insulin has a very short duration of action (minutes), and the onset of basal subcutaneous insulin is 1–2 hours. Thus, IV insulin should be continued for 1–2 hours after the first administration of subcutaneous basal insulin.

Once a patient has been identified as needing to transition to subcutaneous insulin, the patient’s 24-hour insulin requirement can be calculated by extrapolating from the average IV dose required over the previous 6–8 hours in a stable patient. Most authorities recommend using 60–80% of the total daily insulin requirement calculated from the insulin infusion rate to minimize the risk of hypoglycemia. An additional factor to consider is the caloric intake of the patient while on the
insulin infusion protocol. If intake is minimal, the calculated daily insulin dose reflects primarily the patient's basal insulin requirement. If the caloric intake is more substantial (e.g., parenteral or enteral nutrition), the calculated insulin requirement reflects both basal and nutritional insulin requirements. Patients who will be eating will require both basal and prandial insulin, with correction doses as needed. For patients who will be on NPO status or eating very little, basal insulin with correction doses can be used. Several authors have published protocols for the transition from IV to subcutaneous insulin.62–67

Conclusion
Although the past decade has seen great controversy regarding optimal glycemic targets for inpatients, it is clear that extremes of blood glucose lead to poor outcomes, and continuous IV protocols are the preferred treatment modality for glycemic control in the critical care setting. In addition, insulin infusion can be an effective treatment modality in other acute care settings with appropriate glycemic targets, monitoring, and education. The safety of insulin infusion protocols hinges on appropriate blood glucose monitoring and titration. Using a computerized infusion protocol and a continuous blood glucose sensor may allow for tighter glycemic control without increasing hypoglycemia and mortality rates.

References
62van den Bergh G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med 345:1339–1367, 2001
63Bagshaw SM, Egi M, George C, Bellomo R; Australia New Zealand Intensive Care Society Database Management Committee: Early blood glucose control and mortality in critically ill patients in Australia. Crit Care Med 37:463–470, 2009
64Falciglia M, Freyberg RW, Almenoff PL, D’Alessio DA, Render ML: Hyperglycemia: an independent marker of in-hospital mortality in critically ill patients with undiagnosed diabetes. J Clin Endocrinol Metab 87:978–982, 2002
65Finney SJ, Ziekveld C, Elia A, Evans TW: Glucose control and mortality in critically ill patients. JAMA 290:2041–2047, 2003
66Freire AX, Bridges L, Umpierrez GE, Kuhl D, Kitabchi AE: Admission hyperglycemia and other risk factors as predictors of hospital mortality in a medical ICU population. Chest 128:3109–3116, 2005
67Krisley JS: Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 78:1471–1478, 2003
68Garber AJ, Moghissi ES, Bransome ED Jr, Clark NG, Clement S, Cobbin RH, Furnary AP, Hirsch IB, Levy P, Roberts R, Van den Bergh G, Zamudio V; American College of Endocrinology Task Force on Inpatient Diabetes Metabolic Control: American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 10:77–82, 2004
69Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P; American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism: Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 117:1610–1619, 2008
70Arab Y, Dabbagh OC, Tamin HM, Al-Shumener AA, Memish ZA, Haddad SH, Saeed SJ, Girishar HR, Roshan AH, Al-Fekki MO, Ka’ohul SH, Britts RJ, Sakjiha MH: Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med 36:1390–1397, 2008
71Bruhnhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Grundling M, Oppert M, Grond S, Othoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehnkopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, German Competence Network Sepsis (SepNet): Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139, 2008
72Preiser JC, Devos P, Rauz-Santana S, Melot C, Annane D, Groeneveld J, Lapichino G, Leverve X, Nitenberg G, Onesti J, Joannidis M, Stecher A, Cholero R: A prospective randomised multicentre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glicoreg study. Intensive Care Med 35:1738–1748, 2009
73van den Bergh G, Wilmer A, Hermans G, Meerseman W, Wouters PJ, Milants I, Van Wingaerden E, Bobbaers H, Bouillon R: Intensive insulin therapy in the medical ICU. N Engl J Med 354:449–461, 2006
74NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Hebert PC, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG; Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283–1297, 2009
75NICE-SUGAR Study Investigators; Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, McArthur C, Mitchell I, Foster D, Dhingra V, Henderson WR, Ronco JJ, de Miguel-Yanes JM, Munoz-Gonzalez J, Anduze-Lillo JA, Moyano-Villaseca B, Gonzalez-Ramallo VJ; Bustamante-Fernosso A: Implementation of a bundle of actions to improve adherence to the Surviving Sepsis Campaign guidelines at the ED. Am J Emerg Med 27:668–674, 2009
76Kavanagh BP, McCowen KC: Clinical practice: glycemic control in the ICU. N Engl J Med 363:2540–2546, 2010
77Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismaili-Begi F, Kirmack RS, Umpierrez GE; American Association of Clinical Endocrinologists, American Diabetes Association: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract 15:353–369, 2009
78Jacobi J, Bircher N, Krisley J, Agus M, Braithwaite SS, Deutschman C, Freire AX, Geehan D, Kohl B, Nasraway SA, Rugby M, Sands K, Schallom L, Taylor B, Umpierrez G, Mazuzski J, Schumenn H: Guidelines for the use of insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med 40:3251–3276, 2012
79Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith SP, Schafer RG, Hirsch IB; American Diabetes Association Diabetes in Hospitals Working Committee: Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27:553–591, 2004
80Cohen MR: Pharmacists’ role in ensuring safe and effective hospital use of insulin. Am J Health Syst Pharm 67:517–521, 2010
81Institute for Safe Medication Practices: ISMP’s list of high-alert medications. Available from www.ismp.org/Tools/highalertmedications.pdf. Accessed 13 April 2014
82Hellman R: A systems approach to reducing errors in insulin therapy in the inpatient setting. Endocr Pract 10 (Suppl.2):100–108, 2004
83Joint Commission: High-alert medications and patient safety. Available from www.jointcommission.org/sentinel_event_alert_issue_11_high-alert_medications_and_patient_safety. Accessed 13 April 2014
84Browning LA, Dumo P: Sliding-scale insulin: an antiquated approach to glycemic control in hospitalized patients. Am J Health Syst Pharm 61:1611–1614, 2004
85Ku SY, Sayre CA, Hirsch IB, Kelly JL: New insulin infusion protocol improves blood glucose control in hospitalized patients without increasing hypoglycemia. Jt Comm J Qual Patient Saf 31:141–147, 2005
86DeSantis AJ, Schmelz LR, Schmidt K, O’Shea-Mahler E, Rhee C, Wells A, Brandt S, Peterson S, Molitch ME: Inpatient management of hyperglycemia: the Northwestern experience. Endocr Pract 12:491–505, 2006
87Munoz M, Pronovost P, Dintzis J, Kemmerer T, Wang NY, Chang YT, Efrid L, Berenholtz SM, Golden SH: Implementing and evaluating a multicomponent inpatient diabetes management program: putting research into practice. Jt Comm J Qual Patient Saf 38:195–206, 2012
88Newton CA, Young S: Financial implications of glycemic control: results of an inpatient diabetes management program. Endocr Pract 12 (Suppl.3):43–48, 2005
89Olson L, Muchmore J, Lawrence CB: The benefits of an inpatient diabetes care: improving quality of care and the bottom line. Endocr Pract 12 (Suppl.3):35–42, 2006
90Osborne RC, Cook CB, Stockton L, Baird M, Harmon V, Keddo A, Pounds T, Lowe Y, Reid J, McGowan KA, Davidson PC: Improving hyperglycemia management in the intensive care
Pharmacy and Therapeutics

unit: preliminary report of a nurse-driven quality improvement project using a redesigned insulin infusion algorithm. Diabetes Educ. 32:394–403, 2006
12Reynolds LR, Cook AM, Lewis DA, Collier MC, Legg SS, Barnes NG, Congiolaro J, Lofgren RP: An institutional process to improve inpatient glycemic control. Qual Manag Health Care 16:239–249, 2007
13Furnary AP: Insulin infusions for cardiac surgery patients with diabetes: a call to reason. Endocr Pract 8:71–72, 2002
14Kinslay JS: Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79:992–1000, 2004
15Markowitz LJ, Wiechmann RJ, Harris N, Hayden V, Cooper J, Johnson G, Harelbad R, Calkins L, Braithwaite SS: Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery. Endocr Pract 8:10–18, 2002
16Shetty S, Inzucchi SE, Goldberg PA, Cooper D, Siegel MD, Hontvedt S: Adapting to the new consensus guidelines for managing hyperglycemia during critical illness: the updated Yale insulin infusion protocol. Endocr Pract 18:363–370, 2012
17Wilson M, Weinrich J, Hoo GW: Intensive insulin therapy in critical care: a review of 12 protocols. Diabetes Care 30:1005–1011, 2007
18Bouw JW, Campbell N, Hull MA, Juneja R, Guzman O, Overholser BR: A retrospective cohort study of a nurse-driven computerized insulin infusion program versus a paper-based protocol in critically ill patients. Diabetes Technol Ther 14:123–130, 2012
19Dortch MJ, Mowery NT, Ozdas A, Dosssett L, Cao H, Collier B, Holder G, Miller RA, May AK: A computerized insulin infusion titration protocol improves glucose control with less hypoglycemia compared to a manual titration protocol in a trauma intensive care unit. J Parenter Enteral Nutr 32:18–27, 2008
20Hoekstra M, Vogelzang M, Verbitskiy E, Nijsten MW: Health technology assessment review: continuous measurement of blood glucose: validation, reliability, and clinical accuracy. J Hosp Med 3:339–347, 2008
21Lee J, Forlilage D, Box K, Sakaratus L, Bhavsar D, Coimbra R, Potenza B: Computerized insulin infusion programs are safe and effective in the burn intensive care unit. J Burn Care Res 33:e114–e119, 2012
22Magee MC: Improving IV insulin administration in a community hospital. J VI Exp Med 64:3705, 2012 (doi: 10.3719/3705)
23Marvin MR, Inzucchi SE, Besterman BJ: Computerization of the Yale insulin infusion protocol and potential insights into causes of hypoglycemia with intravenous insulin. Diabetes Technol Ther 15:246–252, 2013
24Olinghouse C: Development of a computerized intravenous insulin application (AutoCal) at Kaiser Permanente Northwest, integrated into Kaiser Permanente HealthConnect: impact on safety and nursing workload. Perm J 16:67–70, 2012
25Faranon-Pogacean C, Banasaik Ki, Hirshberg EL, Faustino EV: Comparison of the effectiveness and safety of two insulin infusion protocols in the management of hyperglycemia in critically ill children. Pediatr Crit Care Med 11:741–749, 2010
26Krikorian A, Ismail-Beigi F, Moghissi ES: Comparisons of different insulin infusion protocols: a review of recent literature. Eur J Clin Nutr Metab Care 13:198–204, 2010
27Juneja R, Rondebush CP, Nasraway SA, Golas AA, Jacobs J, Carroll J, Nelson D, Abad VJ, Flanders SJ: Computerized intensive insulin dosing can mitigate hypoglycemia and achieve tight glycemic control when glucose measurement is performed frequently and on time. Crit Care 13:R163, 2009 (doi: 10.1186/cc8129)
28Newton CA, Smiley D, Bode BW, Kitabchi AE, Davidson PC, Jacobs S, Steed RD, Stente F, Peng L, Mulligan P, Freire AX, Temponi A, Umpierrez GE: A comparison study of continuous insulin infusion protocols in the medical intensive care unit: computer-guided vs. standard column-based algorithms. J Hosp Med 5:432–437, 2010
29Sood R, Zieger M, Roggy D, Nazim M, Henderson SR, Hartman B: The effectiveness of a computerized IV insulin protocol to treat hyperglycemia in burn patients. J Burn Care Res 33:638–641, 2012
30Wiener RS, Wiener DC, Larson RJ: Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 300:933–944, 2008
31Dungan K, Chapman J, Braithwaite SS, Buse J: Glucose measurement: confounding issues in setting targets for inpatient management. Diabetes Care 30:403–409, 2007
32U.S. Food and Drug Administration: Blood glucose monitoring test systems for prescription point-of-care use: draft guidance for industry and Food and Drug Administration staff. Available from http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM380352.pdf. Accessed 5 June 2014
33Goldberg PA, Siegel MD, Russell RR, Sherwin RS, Halickman JJ, Cooper DA, Dezura JD, Inzucchi SE: Experience with the continuous glucose monitoring system in a medical intensive care unit. Diabetes Technol Ther 6:359–347, 2004
34Rabiee A, Andreasik V, Abu-Hamdah R, Galiasatos P, Khouri Z, Gibson BR, Andersen DK, Elahi D: Numerical and clinical accuracy of a continuous glucose monitoring system during intravenous insulin therapy in the surgical and burn intensive care units. J Diabetes Sci Technol 3:951–959, 2009
35Yamashita K, Okabayashi T, Yokoyama T, Yatabe T, Maeda H, Manabe M, Hanazaki K: Accuracy and reliability of continuous blood glucose monitor in post-surgical patients. Acta Anaesthesiol Scand 53:66–71, 2009
36Skaervold NK, Sollsaid E, Hjelme DR, Aadahl P: Continuous measurement of blood glucose: validation of a new intravascular sensor. Anesthesiology 114:120–125, 2011
37Mendez CE, Mok KT, Ata A, Tanenberg RJ, Callies-Escandon J, Umpierrez GE: Increased glycemic variability is independently associated with length of stay and mortality in noncritically ill hospitalized patients. Diabetes Care 36:4091–4097, 2013
38Hoofnagle AN, Peterson GN, Kelly JL, Sayre CA, Clou D, Hirsch JB: Use of serum and plasma glucose measurements as a benchmark for improved hospital-wide glycemic control. Endocr Pract 14:536–563, 2008
39Kinsley JS, Jones RL: Cost analysis of intensive glycemic control in critically ill adults. Crit Care Med 34:612–616, 2006
40van den Bergh G, Wouters PJ, Kesteloot K, Hilleman DE: Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med 34:612–616, 2006
41Umpierrez GE, Hellman R, Koryktowski MT, Kosiborod M, Maynard GA, Montori VM, Selye JJ, van den Bergh G, Endocrine Society: Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:16–38, 2012
42Bode BW, Braithwaite SS, Steed RD, Davidson PC: Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy. Endocr Pract 10 (Suppl. 2):71–80, 2004
43Furnary AP, Braithwaite SS: Effects of outcome on in-hospital transition from intravenous insulin infusion to subcutaneous therapy. Am J Cardiol 98:557–564, 2006
44Olansky L, Sam S, Lober C, Yared JP, Hoogwerf B: Cleveland Clinic cardiovascular intensive care unit insulin conversion protocol. J Diabetes Sci Technol 3:478–486, 2009
45Schmelz LR, DeSansit AJ, Schmidt K, O’Shea-Mahler E, Rhee C, Brandt S, Peterson S, Molitch ME: Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Endocr Pract 12:641–650, 2006
46Larsen J, Goldner W: Approach to the hospitalized patient with severe insulin resistance. J Clin Endocrinol Metab 96:2652–2662, 2011
47Kelly JL: Ensuring optimal insulin utilization in the hospital setting: role of the pharmacist. Am J Health Syst Pharm 67:589–596, 2010

Janet L. Kelly, PharmD, BC-ADM, is an outcomes and cost management pharmacist and director of pharmacy residency programs at the University of Washington Medical Center in Seattle.

© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details.